Bis Marck Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 5 Year, 17 Days
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 5.00 M
- Revenue Growth 535.72%
- Profit Growth 2615.56%
- Ebitda 2641.22%
- Net Worth 148.19%
- Total Assets 138.29%
About Bis Marck Pharmaceuticals
Bis Marck Pharmaceuticals Private Limited (BMPPL) is a Private Limited Indian Non-Government Company incorporated in India on 04 February 2020 (Five years 17 days old ). Its registered office is in Rajkot, Gujarat, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹5.00 M.
Dhara Kothari, Maheshbhai Gondaliya, Vishal Kamani, and One other member serve as directors at the Company.
Company Details
- Location
Rajkot, Gujarat, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U33100GJ2020PTC112496
- Company No.
112496
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Feb 2020
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Who are the key members and board of directors at Bis Marck Pharmaceuticals?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Dhara Kothari  | Director | 04-Feb-2020 | Current |
| Maheshbhai Gondaliya | Director | 04-Feb-2020 | Current |
| Vishal Kamani | Director | 04-Feb-2020 | Current |
| Yash Kakaiya | Director | 30-Jun-2020 | Current |
Financial Performance of Bis Marck Pharmaceuticals.
Bis Marck Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 535.72% increase. The company also saw a substantial improvement in profitability, with a 2615.56% increase in profit. The company's net worth Soared by an impressive increase of 148.19%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Bis Marck Pharmaceuticals?
In 2022, Bis Marck Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹5.00 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.50 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 22 Mar 2024 | Others | ₹5.00 M | Open |
How Many Employees Work at Bis Marck Pharmaceuticals?
Unlock and access historical data on people associated with Bis Marck Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Bis Marck Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bis Marck Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.